Previous 10 | Next 10 |
– Company expects to complete Phase 1/2a studies of STK-001 in children and adolescents with Dravet syndrome in 2023 in order to initiate a Phase 3 program in 2024 – – Company on track to provide additional safety and seizure frequency data from patients who r...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will be participating at the following upcoming investor conferences: ...
Summary STOK went down steadily over the past two years. Its derisking Dravet data did not help either. I think the stock may be undervalued, or at least unfairly or prematurely valued. Two years ago, when I covered Stoke Therapeutics ( STOK ), I said it was workin...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the virtual SVB Securities Global Biopharma Conference on...
– Additional safety and seizure frequency data from patients treated with multiple doses of STK-001 (45mg) anticipated in mid-2023 – – Data from the highest dose cohort (70mg) anticipated in the second half of 2023 – – Company expects to complete...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tues...
– Single and multiple doses of STK-001 up to 45mg were well-tolerated – – 55% median reduction from baseline in convulsive seizure frequency was observed among patients treated with three doses of 45mg (n=6) – – Benefits of treatment with STK...
– Seven abstracts related to the Company’s work in Dravet syndrome will be presented, including data from a combined interim analysis of the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnol...
Clinical-stage biotech Stoke Therapeutics ( NASDAQ: STOK ) shed ~28% after reporting interim data from two ongoing Phase 1/2a trials for STK-001, a candidate targeted at the genetic epilepsy disorder Dravet syndrome. More than 90% of patients with seizures linked to Drav...
Stoke Therapeutics press release ( NASDAQ: STOK ): Q3 GAAP EPS of -$0.66 beats by $0.02 . Revenue of $2.91M beats by $0.19M . As of September 30, 2022, Company had $252.2M in cash, cash equivalents, marketable securities, and restricted cash, anticipated to fun...
News, Short Squeeze, Breakout and More Instantly...
Stoke Therapeutics Inc. Company Name:
STOK Stock Symbol:
NYSE Market:
Stoke Therapeutics Inc. Website:
2024-06-16 20:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldma...
2024-05-16 08:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...